NTrans Technologies (NTrans) is developing a gene-editing therapy for the muscle disease Duchenne (DMD). The patented therapeutic platform activates a cell's natural uptake mechanism to safely deliver gene-editing systems, such as CRIPR-Cas9, into a target cell, where it efficiently restores the function of the defective gene.
 
The Mibiton funding will be used to purchase advanced equipment to support the development process at NTrans.